DOCSLIB.ORG

GKV- Arzneimittelindex

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
GKV- Arzneimittelindex GKV-Arzneimitelindex GKV- Arzneimittelindex Stand: 16. Dezember 2004 Uwe Fricke Anatomisch- Anette Zawinell therapeutisch-chemische Klassifikation mit Tagesdosen für den deutschen Arzneimittel- markt gemäß § 73 Abs. 8 Satz 5 SGB V. – Angenommene Beschlussvorlage der ATC-Arbeitsgruppe des Kuratoriums für Fragen der Klassifikation im Gesundheits- wesen am 3. Dezember 2004 GKV-Arzneimittelindex GKV-Arzneimittelindex Anatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen für den deutschen Arzneimittelmarkt ge- mäß § 73 Abs. 8 Satz 5 SGB V. – Beschlussvorlage für die ATC-Arbeitsgruppe des Kuratoriums für Fragen der Klassifikation im Gesund- heitswesen am 3. Dezember 2004 Bonn, im Dezember 2004 Herausgeber: Wissenschaftliches Institut der AOK (WIdO) Kortrijker Straße 1 53177 Bonn Tel.: 0228/843 393 Fax: 0228/843 144 www.wido.de email: [email protected] Autoren: Prof. Dr. rer. nat. Uwe Fricke Institut für Pharmakologie Klinikum der Universität zu Köln Gleueler Str. 24 50931 Köln email: [email protected] Dr. rer. nat. Anette Zawinell Wissenschaftliches Institut der AOK Kortrijker Str. 1 53177 Bonn email: [email protected] Layout: Heidi Klinger Grafik: Ulrich Birtel Pharmazeutisch-technische Assistenz: Gudrun Billesfeld Sylvia Ehrle Andrea Hall Sandra Heric Manuela Steden Homepage: Aktuelle Informationen zum Thema erhalten Sie unter www.wido.de. 2 GKV-Arzneimittelindex Die vorliegende Publikation wurde im Rahmen des Forschungsprojekts GKV- Arzneimittelindex erstellt: Träger des GKV-Arzneimittelindex AOK-Bundesverband, Bonn BKK Bundesverband, Essen IKK-Bundesverband, Bergisch Gladbach Bundesverband der landwirtschaftlichen Krankenkassen, Kassel Verband der Angestellten-Krankenkassen e.V., Siegburg Arbeiter-Ersatzkassen-Verband e.V., Siegburg Bundesknappschaft, Bochum Kassenärztliche Bundesvereinigung, Berlin Zentralinstitut für die kassenärztliche Versorgung in der Bundesrepublik Deutschland, Berlin ABDA – Bundesvereinigung Deutscher Apothekerverbände/ Deutscher Apo- thekerverband e.V., Berlin Dieses Werk ist urheberrechtlich geschützt. Die dadurch begründeten Rechte, insbesondere die der Übersetzung, des Nachdrucks, des Vortrags, der Ent- nahme von Abbildungen und Tabellen, der Funksendung, der Mikroverfilmung oder der Vervielfältigung auf anderen Wegen und der Speicherung in Daten- verarbeitungsanlagen bleiben auch bei nur auszugsweiser Verwertung vorbe- halten. Eine Vervielfältigung dieses Werkes oder von Teilen dieses Werkes ist auch im Einzelfall nur in den Grenzen der gesetzlichen Bestimmungen des Urheberrechtsgesetzes der Bundesrepublik Deutschland vom 9. September 1965 in der jeweils geltenden Fassung zulässig. Sie ist grundsätzlich vergü- tungspflichtig. Zuwiderhandlungen unterliegen den Strafbestimmungen des Urheberrechtsgesetzes. 3 GKV-Arzneimittelindex Die vorliegende Publikation ist ein Beitrag des GKV-Arzneimittelindex im Wis- senschaftlichen Institut der AOK (WIdO) und weder eine Meinungsäußerung des AOK-Bundesverbandes noch des WHO Collaborating Centre for Drug Statistics Methodology. Die Verwendung von Teilen der Original-WHO- Publikation „Guidelines for ATC classification and DDD assignment“ für die Klassifikationsarbeiten im GKV-Arzneimittelindex im WIdO wurden dem WHO Collaborating Centre for Drug Statistics Methodology angezeigt. Wichtiger Hinweis Die Erkenntnisse in der Medizin unterliegen laufendem Wandel durch For- schung und klinische Erfahrungen. Sie sind darüber hinaus vom wissen- schaftlichen Standpunkt der Beteiligten als Ausdruck wertenden Dafürhaltens geprägt. Wegen der großen Datenfülle sind Unrichtigkeiten gleichwohl nicht immer auszuschließen. Alle Angaben erfolgen insoweit nach bestem Wissen, aber ohne Gewähr. Produkthaftung: Für Angaben über Dosierungshinweise und Applikationsformen können Autoren, Herausgeber und Verlag keine Ge- währ übernehmen. Derartige Angaben müssen vom jeweiligen Anwender im Einzelfall anhand anderer Literaturstellen und anhand der Beipackzettel der verwendeten Präparate in eigener Verantwortung auf ihre Richtigkeit über- prüft werden. 4 GKV-Arzneimittelindex Wissenschaftliche Berater des GKV-Arzneimittelindex: Prof. Dr. med. Björn Lemmer Institut für Pharmakologie und Toxikologie Ruprecht-Karls-Universität Heidelberg Universität Heidelberg Maybachstraße 14-16 68169 Mannheim Prof. Dr. med. Martin J. Lohse Institut für Pharmakologie der Universität Würzburg Versbacher Straße 9 97078 Würzburg Dr. med. Klaus Mengel Höferstr. 15 68199 Mannheim Prof. Dr. med. Gerhard Schmidt Zentrum Pharmakologie und Toxikologie der Universität Göttingen Robert-Koch-Straße 40 37075 Göttingen Prof. Dr. med. Hasso Scholz Institut für Experimentelle und klinische Pharmakologie und Toxikologie Universitäts-Krankenhaus Eppendorf Martinstraße 52 20246 Hamburg 5 Vorwort Vorwort Der GKV-Arzneimittelindex im Wissenschaftlichen Institut der AOK (WIdO) unter der gemeinsamen Trägerschaft der Spitzenverbände der Krankenkas- sen, der Kassenärztlichen Bundesvereinigung, des Zentralinstituts für die kassenärztliche Versorgung sowie der Bundesvereinigung Deutscher Apothe- kerverbände sorgt seit 1981 für Transparenz im deutschen Arzneimittelmarkt. Dabei wird die Erfassung von Umfang und Struktur der vertragsärztlichen Arzneimittelverordnungen in Deutschland erst dadurch ermöglicht, dass das anatomisch-therapeutisch-chemische Klassifikationssystem (ATC-System) der Weltgesundheitsorganisation (WHO) als wesentliche methodische Grund- lage im Rahmen des GKV-Arzneimittelindex verwendet wird. Durch eine Kooperation zwischen der Weltgesundheitsorganisation und dem Wissenschaftlichen Institut der AOK (WIdO) wurde die Anwendung dieses ATC-Klassifikationssystems zur Untersuchung des Arzneimittelverbrauchs auch für den deutschsprachigen Nutzer ermöglicht. Seit Januar 2001 steht damit auch diesem Nutzerkreis das von der Weltgesundheitsorganisation erstellte und gepflegte anatomisch-therapeutisch-chemische Klassifikations- system (ATC-Code) mit definierten Tagesdosen zusammen mit einer ausführ- lichen Methodikbeschreibung in der deutschsprachigen Übersetzung zur Ver- fügung. Im Januar 2004 wurde die international gültige ATC-Klassifikation der WHO durch das Bundesministerium für Gesundheit und Soziale Sicherung (BMGS) für amtlich erklärt. Diese Fassung wurde 2004 über das Deutsche Institut für Medizinische Dokumentation und Information (DIMDI) zur Verfü- gung gestellt. Zur Weiterentwicklung des Klassifikations-Systems mit definierten Tagesdo- sen und einer Anpassung an die besonderen Gegebenheiten des deutschen Arzneimittelmarktes wurde im Auftrag des Bundesministeriums für Gesund- heit und Soziale Sicherung (BMGS) eine Arbeitsgruppe beim Kuratorium für Fragen der Klassifikation im Gesundheitswesen eingesetzt, in der die maß- geblichen Fachkreise vertreten sind. Das Bundesministerium für Gesundheit und Soziale Sicherung (BMGS) hat in Zusammenarbeit mit dieser ATC- Arbeitsgruppe im Jahre 2004 beschlossen, bei der Schaffung einer nationalen ATC/DDD-Klassifikation die bereits vorhandene Adaption der WHO- Klassifikation an den deutschen Markt zu Grunde zu legen, die im Rahmen des langjährigen Forschungsprojekts GKV-Arzneimittelindex (GKV-AI) im Wissenschaftlichen Institut der AOK (WIdO) vorliegt. Mit der nun hier vorlie- genden Stellungnahme des GKV-Arzneimittelindex im WIdO wurden die von den pharmazeutischen Herstellern im Rahmen des Anhörungsverfahrens 6 Vorwort eingesammelten Anmerkungen zur bestehenden ATC-Klassifikation und DDD-Festlegung des GKV-Arzneimittelindex inhaltlich geprüft und entspre- chend bewertet. Der GKV-Arzneimittelindex im WIdO wird die Anpassung der ATC-Klassifikation einschließlich der DDD-Angaben auf Beschluss der ATC- Arbeitsgruppe sowie nach Abstimmung mit dem BMGS vornehmen. Diese Fassung kann dann damit 2005 vom BMGS amtlich gemacht werden. Die große Verbreitung der ATC-Klassifikation und DDD-Systematik – sowohl auf nationaler wie auch auf internationaler Ebene – belegt den hohen prakti- schen Nutzen dieser Klassifikation, die nur durch die engagierte Arbeit von Prof. Dr. Uwe Fricke, Dr. Judith Günther und Dr. Anette Zawinell ermöglicht wird. Für ihre engagierte Arbeit möchten wir uns an dieser Stelle bedanken, da nur ihr unermüdlicher Einsatz eine Klassifikationsdatenbank wie die des GKV-Arzneimittelindex – mit inzwischen mehr als 135.000 Arzneimitteleinträ- gen – am Leben erhält sowie die vorliegende Publikation ermöglicht hat. Wir möchten darüber hinaus den pharmakologischen Gutachtern des GKV- Arzneimittelindex Prof. Dr. Björn Lemmer, Prof. Dr. Martin J. Lohse, Dr. Klaus Mengel, Prof. Dr. Gerhard Schmidt und Prof. Dr. Hasso Scholz unseren be- sonderen Dank für die langjährige fachliche Unterstützung aussprechen. Un- ser Dank gilt weiterhin den pharmazeutischen Assistenzkräften im GKV- Arzneimittelindex Gudrun Billesfeld, Sylvia Ehrle, Andrea Hall, Sandra Heric sowie Manuela Steden für ihre tatkräftige Unterstützung. Darüber hinaus dan- ken wir allen, die bei der Fertigstellung der Stellungnahme mitgewirkt haben. Dabei gebührt der Dank insbesondere Gabi Brückner, Kai Bungarz, Andreas Keller, Heidi Klinger und Ulla Mielke im Wissenschaftlichen Institut der AOK (WIdO), die durch die Datenbetreuung, das Erfassen, die Gestaltung der Tex- te sowie die Durchsicht des Manuskripts zum Gelingen dieses Projekts beige- tragen haben. Bonn, im November 2004 Katrin Nink und Helmut Schröder 7 Inhaltsverzeichnis Inhaltsverzeichnis 1 Einleitung......................................................................................................... 12 1.1 Der GKV-Arzneimittelindex............................................................................................
Load more

Recommended publications
  • Dissecting the Ribosomal Inhibition Mechanism of a New Ketolide Carrying an Alkyl-Aryl Group at C-13 of Its Lactone Ring Marios G
    Dissecting the ribosomal inhibition mechanism of a new ketolide carrying an alkyl-aryl group at C-13 of its lactone ring Marios G. Krokidis, Ourania N. Kostopoulou, Dimitrios L. Kalpaxis, George P. Dinos To cite this version: Marios G. Krokidis, Ourania N. Kostopoulou, Dimitrios L. Kalpaxis, George P. Dinos. Dissect- ing the ribosomal inhibition mechanism of a new ketolide carrying an alkyl-aryl group at C-13 of its lactone ring. International Journal of Antimicrobial Agents, Elsevier, 2010, 35 (3), pp.235. 10.1016/j.ijantimicag.2009.11.002. hal-00556385 HAL Id: hal-00556385 https://hal.archives-ouvertes.fr/hal-00556385 Submitted on 16 Jan 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Accepted Manuscript Title: Dissecting the ribosomal inhibition mechanism of a new ketolide carrying an alkyl-aryl group at C-13 of its lactone ring Authors: Marios G. Krokidis, Ourania N. Kostopoulou, Dimitrios L. Kalpaxis, George P. Dinos PII: S0924-8579(09)00511-1 DOI: doi:10.1016/j.ijantimicag.2009.11.002 Reference: ANTAGE 3179 To appear in: International Journal of Antimicrobial Agents Received date: 20-7-2009 Accepted date: 3-11-2009 Please cite this article as: Krokidis MG, Kostopoulou ON, Kalpaxis DL, Dinos GP, Dissecting the ribosomal inhibition mechanism of a new ketolide carrying an alkyl-aryl group at C-13 of its lactone ring, International Journal of Antimicrobial Agents (2008), doi:10.1016/j.ijantimicag.2009.11.002 This is a PDF file of an unedited manuscript that has been accepted for publication.
    [Show full text]
  • Nature Nurtures the Design of New Semi-Synthetic Macrolide Antibiotics
    The Journal of Antibiotics (2017) 70, 527–533 OPEN Official journal of the Japan Antibiotics Research Association www.nature.com/ja REVIEW ARTICLE Nature nurtures the design of new semi-synthetic macrolide antibiotics Prabhavathi Fernandes, Evan Martens and David Pereira Erythromycin and its analogs are used to treat respiratory tract and other infections. The broad use of these antibiotics during the last 5 decades has led to resistance that can range from 20% to over 70% in certain parts of the world. Efforts to find macrolides that were active against macrolide-resistant strains led to the development of erythromycin analogs with alkyl-aryl side chains that mimicked the sugar side chain of 16-membered macrolides, such as tylosin. Further modifications were made to improve the potency of these molecules by removal of the cladinose sugar to obtain a smaller molecule, a modification that was learned from an older macrolide, pikromycin. A keto group was introduced after removal of the cladinose sugar to make the new ketolide subclass. Only one ketolide, telithromycin, received marketing authorization but because of severe adverse events, it is no longer widely used. Failure to identify the structure-relationship responsible for this clinical toxicity led to discontinuation of many ketolides that were in development. One that did complete clinical development, cethromycin, did not meet clinical efficacy criteria and therefore did not receive marketing approval. Work on developing new macrolides was re-initiated after showing that inhibition of nicotinic acetylcholine receptors by the imidazolyl-pyridine moiety on the side chain of telithromycin was likely responsible for the severe adverse events.
    [Show full text]
  • Intracellular Penetration and Effects of Antibiotics On
    antibiotics Review Intracellular Penetration and Effects of Antibiotics on Staphylococcus aureus Inside Human Neutrophils: A Comprehensive Review Suzanne Bongers 1 , Pien Hellebrekers 1,2 , Luke P.H. Leenen 1, Leo Koenderman 2,3 and Falco Hietbrink 1,* 1 Department of Surgery, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands; [email protected] (S.B.); [email protected] (P.H.); [email protected] (L.P.H.L.) 2 Laboratory of Translational Immunology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands; [email protected] 3 Department of Pulmonology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands * Correspondence: [email protected] Received: 6 April 2019; Accepted: 2 May 2019; Published: 4 May 2019 Abstract: Neutrophils are important assets in defense against invading bacteria like staphylococci. However, (dysfunctioning) neutrophils can also serve as reservoir for pathogens that are able to survive inside the cellular environment. Staphylococcus aureus is a notorious facultative intracellular pathogen. Most vulnerable for neutrophil dysfunction and intracellular infection are immune-deficient patients or, as has recently been described, severely injured patients. These dysfunctional neutrophils can become hide-out spots or “Trojan horses” for S. aureus. This location offers protection to bacteria from most antibiotics and allows transportation of bacteria throughout the body inside moving neutrophils. When neutrophils die, these bacteria are released at different locations. In this review, we therefore focus on the capacity of several groups of antibiotics to enter human neutrophils, kill intracellular S. aureus and affect neutrophil function. We provide an overview of intracellular capacity of available antibiotics to aid in clinical decision making.
    [Show full text]
  • Reflection Paper on the Use of Macrolides, Lincosamides And
    14 November 2011 EMA/CVMP/SAGAM/741087/2009 Committee for Medicinal Products for Veterinary Use (CVMP) Reflection paper on the use of macrolides, lincosamides and streptogramins (MLS) in food-producing animals in the European Union: development of resistance and impact on human and animal health Draft agreed by Scientific Advisory Group on Antimicrobials (SAGAM) 2-3 June 2010 Adoption by CVMP for release for consultation 10 November 2010 End of consultation (for comments) 28 February 2011 Agreed by Scientific Advisory Group on Antimicrobials (SAGAM) 22 September 2011 Adoption by CVMP 12 October 2011 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged. Reflection paper on the use of macrolides, lincosamides and streptogramins (MLS) in food-producing animals in the European Union: development of resistance and impact on human and animal health CVMP recommendations for action Macrolides and lincosamides are used for treatment of diseases that are common in food producing animals including medication of large groups of animals. They are critically important for animal health and therefore it is highly important that they are used prudently to contain resistance against major animal pathogens. In addition, MLS are listed by WHO (AGISAR, 2009) as critically important for the treatment of certain zoonotic infections in humans and risk mitigation measures are needed to reduce the risk for spread of resistance between animals and humans.
    [Show full text]
  • Antibiotic Prescribing – Quality Indicators
    Clinical Microbiology and Infection, Volume 12, Supplement 4, 2006 Antibiotic prescribing – quality indicators P1460 Methods: Medical records from all patients with positive blood Is self-medication with antibiotics in Europe cultures in 2001 were analysed retrospectively. Factors driven by prescribed use? predisposing to infections, results of blood cultures, antibiotic use, and outcome were recorded. L. Grigoryan, F.M. Haaijer-Ruskamp, J.G.M. Burgerhof, Results: The antibiotic use in 226 episodes of true bacteraemia J.E. Degener, R. Deschepper, D. Monnet, A. Di Matteo, were analysed. According to guidelines empirical antibiotic ˚ and the SAR E.A. Scicluna, A. Bara, C. Stalsby Lundborg, J. Birkin treatment should be adjusted in 166 episodes. Antibiotic use was group adjusted in 146 (88%) of these 166 episodes, which led to a Objectives: The occurrence of self-medication with antibiotics narrowing of therapy in 118 (80%) episodes. Compared to has been described in the US and Europe, a possible empirical therapy there was a 22% reduction in the number of contributing factor to increased antibiotic resistance. An antibiotics. Adjustment of therapy was more often performed in important reason for using self-medication can be past Gram-negative bacteraemia and polymicrobial cultures than in experience with antibiotics prescribed by health professionals. Gram-positive bacteraemia. In bacteraemia caused by We investigated whether self-medication in Europe follows the ampicillin-resistant E. coli, ampicillin was mostly replaced by same pattern as prescribed use. ciprofloxacin. The cost for 7 days adjusted therapy was 19800 Methods: A population survey was conducted in: North and EUR (23%) less than for 7 days of empirical therapy.
    [Show full text]
  • Ribosome Assembly As Antimicrobial Target
    antibiotics Article Ribosome Assembly as Antimicrobial Target Rainer Nikolay 1,*,†, Sabine Schmidt 2,†, Renate Schlömer 2, Elke Deuerling 2,* and Knud H. Nierhaus 1 1 Institut für Medizinische Physik und Biophysik, Charité—Universitätsmedizin Berlin, 10117 Berlin, Germany; [email protected] 2 Molecular Microbiology, University of Konstanz, Konstanz 78457, Germany; [email protected] (S.S.); [email protected] (R.S.) * Correspondence: [email protected] (R.N.); [email protected] (E.D.); Tel.: +49-30-450-524165 (R.N.); +49-7531-88-2647 (E.D.) † These authors contributed equally to this work. Academic Editor: Claudio O. Gualerzi Received: 31 March 2016; Accepted: 16 May 2016; Published: 27 May 2016 Abstract: Many antibiotics target the ribosome and interfere with its translation cycle. Since translation is the source of all cellular proteins including ribosomal proteins, protein synthesis and ribosome assembly are interdependent. As a consequence, the activity of translation inhibitors might indirectly cause defective ribosome assembly. Due to the difficulty in distinguishing between direct and indirect effects, and because assembly is probably a target in its own right, concepts are needed to identify small molecules that directly inhibit ribosome assembly. Here, we summarize the basic facts of ribosome targeting antibiotics. Furthermore, we present an in vivo screening strategy that focuses on ribosome assembly by a direct fluorescence based read-out that aims to identify and characterize small molecules acting as primary assembly inhibitors. Keywords: protein synthesis as preferential target of antibiotics; ribosome as antibiotic target; inhibitors of ribosome assembly; concepts for identifying assembly inhibitors 1. Introduction Most antibiotics are microbial secondary metabolites mainly produced by actinomycetes.
    [Show full text]
  • Azalides from Azithromycin to New Azalide Derivatives Stjepan Mutak
    J. Antibiot. 60(2): 85–122, 2007 THE JOURNAL OF REVIEW ARTICLE ANTIBIOTICS Azalides from Azithromycin to New Azalide Derivatives Stjepan Mutak Received: August 22, 2006 / Accepted: January 22, 2007 © Japan Antibiotics Research Association Abstract Azalides are semi-synthetic macrolides, in which a nitrogen atom is introduced into a macrolactone ring via a Beckmann rearrangement. Starting from erythromycin, oximes, depending on the reaction conditions lactams, or bicyclic-imino-ethers were formed, which were further reduced to aminolactones. The cyclic amine 9a- became the precursor for novel, significantly more active derivatives, especially for 9-dihydro-9-deoxo-9a-methyl-9a-aza-9a- homoerythromycin A with the generic name azithromycin. It showed a broad spectrum of antibacterial activity covering all significant bacteria causing respiratory tract infections. The greatest advantages of azithromycin are its unusual pharmacokinetics (high tissue distribution), metabolic stability and high tolerability. These properties have led in recent years to the widespread use of the azalide scaffold for the synthesis of new compounds with advantageous pharmacokinetics. The azalide scaffold possesses an amino and several hydroxyl groups, which could be substituted or transformed to obtain new compounds. Different derivatives were obtained by substitution on the nitrogen but a large variety of derivatives, such as ethers, esters and carbamates, were made by reactions with various hydroxyl groups. Substitutions on both nitrogen and hydroxyl or two hydroxyl groups yielded new, bridged compounds. The 4Љ- hydroxy group was oxidized to 4-oxo-, which was transformed via the oxime to 4-amino, or via epoxide to 4Љ-methylamino compounds. Cleavage of the cladinose sugar and further transformations gave 3-acyl or 3-oxo compounds, which were less active than 14-membered acylides or ketolides.
    [Show full text]
  • Lincosamide-Streptogramin Group of Antibiotics and Its Genetic Linkage – a Review
    Annals of Agricultural and Environmental Medicine 2017, Vol 24, No 2, 338–344 www.aaem.pl ORIGINAL ARTICLE Resistance to the tetracyclines and macrolide- lincosamide-streptogramin group of antibiotics and its genetic linkage – a review Durdica Marosevic1*, Marija Kaevska1, Zoran Jaglic1 1 Veterinary Research Institute, Brno, Czech Republic Marosevic D, Kaevska M, Jaglic Z. Resistance to the tetracyclines and macrolide-lincosamide-streptogramin group of antibiotics and its genetic linkage – a review. Ann Agric Environ Med. 2017; 24(2): 338–344. https://doi.org/10.26444/aaem/74718 Abstract An excessive use of antimicrobial agents poses a risk for the selection of resistant bacteria. Of particular interest are antibiotics that have large consumption rates in both veterinary and human medicine, such as the tetracyclines and macrolide- lincosamide-streptogramin (MLS) group of antibiotics. A high load of these agents increases the risk of transmission of resistant bacteria and/or resistance determinants to humans, leading to a subsequent therapeutic failure. An increasing incidence of bacteria resistant to both tetracyclines and MLS antibiotics has been recently observed. This review summarizes the current knowledge on different tetracycline and MLS resistance genes that can be linked together on transposable elements. Key words antibiotics, genetic determinants of resistance, transposons, transmission of resistance INTRODUCTION AND BACKGROUND Table 1. List of approved tetracyclines, macrolides, lincosamides and streptogramins for human or veterinary use in European Union (2011_ Adriaenssens, 1999_EMEA). An excessive use of antimicrobial agents poses a risk for http://www.chemeurope.com/en/encyclopedia/ATC_code_J01. the selection of resistant bacteria, which could be either html#J01AA_Tetracyclines causative agents of a specific disease or a reservoir of genetic determinants of resistance.
    [Show full text]
  • Ribosome Protection Proteins—“New” Players in the Global Arms Race with Antibiotic-Resistant Pathogens
    International Journal of Molecular Sciences Review Ribosome Protection Proteins—“New” Players in the Global Arms Race with Antibiotic-Resistant Pathogens Rya Ero 1,2,*, Xin-Fu Yan 2 and Yong-Gui Gao 2,3,* 1 Department of Molecular Biology, Institute of Molecular and Cell Biology, University of Tartu, 51010 Tartu, Estonia 2 School of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore; [email protected] 3 NTU Institute of Structural Biology, Nanyang Technological University, Singapore 639798, Singapore * Correspondence: [email protected] (R.E.); [email protected] (Y.-G.G.); Tel.: +372-737-5032 (R.E.); +65-6908-2211 (Y.-G.G.) Abstract: Bacteria have evolved an array of mechanisms enabling them to resist the inhibitory effect of antibiotics, a significant proportion of which target the ribosome. Indeed, resistance mechanisms have been identified for nearly every antibiotic that is currently used in clinical practice. With the ever-increasing list of multi-drug-resistant pathogens and very few novel antibiotics in the pharma- ceutical pipeline, treatable infections are likely to become life-threatening once again. Most of the prevalent resistance mechanisms are well understood and their clinical significance is recognized. In contrast, ribosome protection protein-mediated resistance has flown under the radar for a long time and has been considered a minor factor in the clinical setting. Not until the recent discovery of the ATP-binding cassette family F protein-mediated resistance in an extensive list of human pathogens has the significance of ribosome protection proteins been truly appreciated. Understanding the Citation: Ero, R.; Yan, X.-F.; Gao, underlying resistance mechanism has the potential to guide the development of novel therapeutic Y.-G.
    [Show full text]
  • Antibiotics Currently in Clinical Development
    A data table from June 2014 Antibiotics Currently in Clinical Development As of June 2014, there are at least 43 new antibiotics1 with the potential to treat serious bacterial infections in clinical development for the U.S. market. The success rate for drug development is low; at best, only 1 in 5 candidates that enter human testing will be approved for patients.* This snapshot of the antibiotic pipeline will be updated periodically as products advance or are known to drop out of development. Please contact Rachel Zetts at [email protected] or 202-540-6557 with additions or updates. Cited for Potential Development Known QIDP4 Drug Name Company Drug Class Activity Against Gram- Potential Indication(s)5 Phase2 Designation? Negative Pathogens?3 Acute bacterial skin and skin structure Approved - infections, hospital acquired bacterial Tedizolid Cubist Pharmaceuticals Oxazolidinone Yes June 20, 2014 pneumonia/ventilator acquired bacterial pneumonia Approved - Acute bacterial skin and skin structure Dalbavancin Durata Therapeutics Lipoglycopeptide Yes May 23, 2014 infections New Drug Application Acute bacterial skin and skin structure Oritavancin The Medicines Company Glycopeptide Yes (NDA) submitted infections New Drug Application (NDA) submitted (for Complicated urinary tract infections, complicated urinary complicated intra-abdominal infections, Novel cephalosporin+beta- Ceftolozane+Tazobactam8 tract infection and Cubist Pharmaceuticals Yes Yes acute pyelonephritis (kidney infection), lactamase inhibitor complicated intra- hospital-acquired
    [Show full text]
  • The Evolving Role of Chemical Synthesis in Antibacterial Drug Discovery Peter M
    Angewandte. Reviews A. G. Myers et al. DOI: 10.1002/anie.201310843 Antibiotic Development The Evolving Role of Chemical Synthesis in Antibacterial Drug Discovery Peter M. Wright, Ian B. Seiple, and Andrew G. Myers* Keywords: antibiotics · chemical synthesis · drug discovery · semisynthesis Angewandte Chemie &&&& 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2014, 53,2–32 Ü Ü These are not the final page numbers! Angewandte Antibacterial Drug Discovery Chemie The discovery and implementation of antibiotics in the early twentieth From the Contents century transformed human health and wellbeing. Chemical synthesis enabled the development of the first antibacterial substances, orga- 1. Introduction 3 noarsenicals and sulfa drugs, but these were soon outshone by a host of 2. Chemical Synthesis Ushers in more powerful and vastly more complex antibiotics from nature: the Golden Age of Antibiotics penicillin, streptomycin, tetracycline, and erythromycin, among others. Discovery 4 These primary defences are now significantly less effective as an unavoidable consequence of rapid evolution of resistance within 3. Semisynthesis: A Powerful Postwar Engine for pathogenic bacteria, made worse by widespread misuse of antibiotics. Antibacterial Discovery 7 For decades medicinal chemists replenished the arsenal of antibiotics by semisynthetic and to a lesser degree fully synthetic routes, but 4. Fully Synthetic Antibacterials, economic factors have led to a subsidence of this effort, which places 1940-Present 13 society on the precipice of a disaster. We believe that the strategic 5. Chemical Synthesis as a Path application of modern chemical synthesis to antibacterial drug Forward 19 discovery must play a critical role if a crisis of global proportions is to be averted.
    [Show full text]
  • 23S Rrna Base Pair 2057–2611 Determines Ketolide Susceptibility and Fitness Cost of the Macrolide Resistance Mutation 2058A3G
    23S rRNA base pair 2057–2611 determines ketolide susceptibility and fitness cost of the macrolide resistance mutation 2058A3G Peter Pfister*†, Natascia Corti*†, Sven Hobbie*, Christian Bruell*, Raz Zarivach‡, Ada Yonath‡§, and Erik C. Bo¨ ttger*§ *Institut fu¨r Medizinische Mikrobiologie, Universita¨t Zu¨ rich, Gloriastrasse 30͞32, CH-8006 Zu¨rich, Switzerland; and ‡Department of Structural Biology, Weizmann Institute, Rehovot 76100, Israel Contributed by Ada Yonath, February 27, 2005 The 23S rRNA A2058G alteration mediates macrolide, lincosamide, Mycobacterium intracellulare (14), Mycobacterium avium (15, 16), and streptogramin B resistance in the bacterial domain and deter- Mycobacterium kansasii (17), Mycobacterium chelonae, Mycobacte- mines the selectivity of macrolide antibiotics for eubacterial ribo- rium abscessus (18), Helicobacter pylori (19–21), Brachyspira (Ser- somes, as opposed to eukaryotic ribosomes. However, this muta- pulina) hyodysenteriae (22), Propionibacterium spp. (23), and Strep- tion is associated with a disparate resistance phenotype: It confers tococcus pneumoniae (24). These mutations have been mapped to high-level resistance to ketolides in mycobacteria but only mar- the macrolide-binding pocket in the ribosomal tunnel, specifically ginally affects ketolide susceptibility in streptococci. We used 23S rRNA nucleotides 2057, 2058, and 2059 in the Escherichia coli site-directed mutagenesis of nucleotides within domain V of 23S numbering system. rRNA to study the molecular basis for this disparity. We show that Nucleotides 2058 and 2059 act as key contact sites for macrolide mutational alteration of the polymorphic 2057–2611 base pair from binding (2, 25). Site-directed mutagenesis has been used to analyze A-U to G-C in isogenic mutants of Mycobacterium smegmatis in detail the role of 23S rRNA nucleotides 2058 and 2059 in significantly affects susceptibility to ketolides but does not influ- drug-target interaction; these studies also alluded to the importance ence susceptibility to other macrolide antibiotics.
    [Show full text]